today's Cathy Jacobsen, Dac, commercial, Thank you, Jennifer, and and Melfi clinical good representing on by Andreas and Nadia call afternoon, our Grauer, Whitaker, joined everyone. collectively Steve functions. finance, regulatory Mike I'm
discussion results, call our first programs. detailed start overview our provide a the before quarter today financial on update questions. of an more summary financial and we XXXX ongoing will by then open an with to Mike I'll development followed
look results at our first the now for Let's quarter. financial
first contract to loss million $X.XX net OMIDRIA Healthcare. was OMIDRIA of we our had last year, of to share, our DRI fourth XXXX Our for difference asset, or a result last per a by of driven quarter In adjustment $XX.X factors. sale million quarter loss the is compared million $XX.X the X as royalty to or remeasurement of royalty a $X.X quarter fourth net per of $X.XX the in of share year. The
of convertible following million a amount a open fourth par million portion the cost notes, $X.X $X.X gain $X.X retirement market a on million or repurchase of of our value. those of XX% a of XXXX notes, at And of of notional quarter early
quarter that of loss been the XXXX transactions, Excluding would fourth net have quarter. current these X our similar to
investments to be we XXXX. on support had debt debt cash amount will into $XXX.X and operations hand operations and an XX, million and service sufficient to ongoing fund of expect March of XXXX, As service available we that
In to $XX.X sales second based to XXXX, January milestone, if with similarly addition, of OMIDRIA, met milestones one milestone in payments Omeros on XXXX. payable payable $XX.X becomes our the negotiated of up January X million million of in
Let's a our earnings now our update month. these call during review We just last development programs. provided comprehensive programs on
the today's be So update brief. lectin of our We'll will complement. with targeting MASP-X start somewhat narsoplimab, inhibitor pathway
application, ongoing last month, BLA. FDA regarding with or our the As discussions biologics described are license resubmission of
transplant-associated in microingeopathy, narsoplimab hematopoietic TA-TMA. cell thrombotic or stem For
time resubmission meetings time, do prescribed the the lines regarding date and Given rules with or for firm this a for date BLA approval. decision we not, related FDA, have at
when last the remain update. of we As in month, with information, narsoplimab. provide optimistic do we'll you We an have I noted that approval
supplying we their meantime, our under access TA-TMA narsoplimab the program physicians. In expanded to continue patients and
program's on strong how grow. transplant Omeros, burden that assessing longer program. for the maintain the given and we'll be community Although, financial to much able within is to Support continues narsoplimab we are
earnings call, last high-risk manuscript expected to is XX in marrow nature's outcome and characteristics, narsoplimab in soon XX the In of a bone patients, treatment our had addition adult be whom to publications recent pediatric to of directed in published discussed the transplantation. real-world
X nocturnal debilitating CXG, potentially Paroxysmal to multiple of studies MASP-X a OMSXXX in complement. rare now pathway indications. disease hemoglobinuria, ongoing Let's or a PNH, or hematologic disorder targeting alternative II OMSXXX, advancing kidney glomerulopathy turn disease. and our life-threatening Phase to the and where is life-threatening inhibitor complement well
largely review went last of in which program a investment Across underrecognized all our being detailed through month's value believe call, clinical perform community. of substantial OMSXXX remains we to extremely continues On our the OMSXXX built value, by date, studies I the to well.
has with development. OMSXXX substantial to to currently us that benefits, or other believe pathway that our including which in iptacopan, compared list our IgA will derisk several inhibitors we as validating other and inhibition programs, of confident by available pathway favorably across clinically Adding pathway a Factor alternative the further summarize, make disease alternative recently, PNH, OMSXXX distinct differentiate confidence, OMSXXX alternative B inhibitors, inhibitor most and CXG. such To efficacy indications, demonstrated nephropathy
OMSXXX we III to differentiators pathway road of approved development. benchmark over targeting detailed in the to we other iptacopan map potential highlight build We've follow continues advantages a what for as MASP-X While either that alternative Phase we on are us and as expect versus pathway OMSXXX alternative targets in to calls, trials between major our designed inhibitors. be, other Iptacopan therapeutics, should. see to the and with previous we or
to be adequate quarterly one, thought is to months shown maintaining include been and intact prevent that: like complement, when CX of to to is superior OMSXXX could dosing entirely underlying examined inhibition an expected of pathway CX and CX consistent inhibitors MASP-X well MASP-X to important the lytic in B, infection-fighting arm two, convenience and not reactant, advantage three, compliance. an unlike the phase be These an Factor breakthrough CX, disease; once has safety; that translate the leave of with once acute and to advantage better dosing, X classical which provide patient and every
by consistently low of a once shown has the favorable research intravenous over oral twice months among preference for drug's response dosing Interestingly, iptacopan. the quarterly of and have daily OMSXXX efficacy burden. date treatment physicians, dosing driven also every X demonstrated expected both, to once a OMSXXX database the physicians Market and the to
usual dosing allow the ensuring would oversee to the patient compliance. follow-up and because physicians patients coincide PNH drug with schedule OMSXXX for administration, is physician regimens This of
dosing sick. a medication the patient's life they regimens extended reminder, of to oral the interval should without allow perspective, From live but normal are OMSXXX the daily them more
II Our X PNH in in clinical well. OMSXXX are our trials program progressing Phase
the inhibitor. stage, In with administration assessing words, other inhibitor and fully or X weeks. complement every OMSXXX The naive, first a every is not patients been have PNH previously has in evaluating who complement XX dose-finding in treated enrolled
second OMSXXX combination to design, therapy, is ravulizumab. enrolling as hemoglobin who PNH the OMSXXX is The with patients patients demonstrated combination administered delivered weeks. ravulizumab response CX in a has trial inhibitor XX And for a who the with have initially suboptimal those monotherapy. to switchover patients in then response these
switchover studies trial for is the long-term completed also OMSXXX we're of The who OMSXXX II efficacy monotherapy have data. study fully enrolling enrolled trial and is Phase and extension safety Third patients X generating our either currently other PNH and program. The an data collecting PNH is
Annual will next Griffin, month. Phase European the from in a St. the recognized an of expert Association, Dr. for been Results have in presentation. II James trial from podium Hematology internationally the of combination R. Leeds, the selected deliver switchover the at stage Hospital the England, presentation PNH Teaching Congress
as reports low-dose now achieved of response. patients with defined in X which presentation is doses group and clinical the the at increase X The X of in of dose different same group patients also hemoglobin the achieved response, results least patients OMSXXX. in PNH All the high an in clinical level X grams of
The directed required action be was of No tolerated mechanism transfusions patients in X concern. safety dose to will well of any either at poster without also following drug EHA initiation of OMSXXX. of presentations pharmacokinetics There signal the group and OMSXXX.
fourth our progress year. to program of III we in OMSXXX the the of Given and PNH quarter performance impressive OMSXXX PNH, Phase in remain rapid this initiate on track
evaluating CXG OMSXXX is clinical II Our Phase in enrolling. trial and
discussions Here first programs, PNH expect in OMSXXX preparation again, begin III we the both are Phase and CXG to European remain a for In program the on Phase of CXG U.S. with track and and III regulators. XXXX. in quarter both ongoing
on data based likelihood patients' OMSXXX to date, conclusion, has So both to believe impact. and market that respect to OMSXXX in of a success, around high we with lives
targeting pathway. I long-acting single administered or OMSXXXX successfully discuss of dose inhibitor subcutaneously OMSXXXX Let's ascending supporting Phase completed once selective intravenously. either quarterly MASP-X, now our study dosing, a
of I Phase to program, is later half expected second to The data OMSXXXX study of multiple dose this team ascending out our quarter. read a that
development neovascular we indications for indicators also these As OMSXXXX. large degeneration, known macular value as Among and disclosed, previously several evaluating of AMD. wet are potential chronic age-related is
valuation in preclinical treatments AMD. be further model demonstrated of mirroring to of previously a approved primate wet was model the Notably OMSXXXX our inhibition qualify effective initiated of AMD. MASP-X To opportunity, all we've a wet AMD and obviously weeks the meaning injections injections Eylea into and of ideal These as every Lucentis not injections, as the eye. posterior such patient chamber X require frequently are for comfort. intravitreal are wet in or required as
in Simply put, a their MASP-X market the therapeutic for exclusively sight systemic or both in their Since MASP-X, produced patients could is physicians. injections in of subcutaneous for benefit maintain large and injection. their allow block intravitreal could potential patients a avoid OMSXXXX the changer administration alone painful eyes, without and game providing to intravenous very liver, need administration
in efforts well in COVID shareholder Phase a select work to quarter and term. OMSXXXX. severe add both next less long including acute in could ongoing HXNX as respiratory indication target value to ARDS, narsoplimab resource-intensive as PAS, the are meaningful With continue or HXNX We and II distress for near with acute or
role international in work generated by diseases. lectin our novel be these continuing team, of to the the support The some of literature, that increasingly central pathway
with pathway As based between patients assay requiring ARDS related on mild those an COVID those part of differentiate lectin and COVID, our efforts, severe activation hospitalization. with that developed can we've
has with ARDS as patients to with of also long patients assay and to well. The other forms potential COVID applicability
molecule, OMSXXXX, orally our narsoplimab, complement MASP-X available both MASP-X and and MASP-X and MASP-X which our small franchise to includes advancing rapidly. addition In are developing and programs, inhibitor antibody of our inhibitors OMSXXX,
well-suited MASP-X inhibitor trials. we ahead, is considering and indications further are Our clinical oral for
quickly our MASP-X leveraging drug oral learned is we MASP-X inhibitor part, good Our candidate, program. development driving that small all a throughout program molecule toward in
disorders directed the Turning aimed inhibitor NIDA. Drug to and the or request program compulsions Abuse, treating on movement Institute OMSXXX, National of our addictions, at PDEX at
year OMSXXX treatment $X.X preclinical receiving The exposed and as results funded grant. NIDA primates is developing a to study million both program cocaine We a for later are potential OMSXXX. from through use this of cocaine by We toxicology a disorder. anticipate
to Also, results disorders, OMSXXX dyskinesias major of we're -induced with L-DOPA the as is referenced in being And we in problem specifically use next most potential study, the therapeutic L-DOPA plan treated in disease. positive individuals cocaine or call, This year patients the disorder. in in use a Parkinson's L-DOPA. inpatient LIDs. OMSXXX a use clinical last Assuming in double-blind initiate evaluating with randomized common trial, toxicology movement exploring month's
a commercial represents and untapped LID such, As market. effectively large
immuno-oncology near-term biologic generate and cellular have value. the to of potential shareholder also platforms set Our
Following is signaling volume our driven both function supersede in immunomodulators the large CAR-T. and exciting antigen-driven could oncotoxins which vaccines, and adoptive therapeutics a cell believe that of therapy, vivo as immunomodulators, primary data, we recent generation of on focus T
to represent surface levels CDX eliminate and the seen targets to designed against to cell inhibitors cancer with time-intensive novel or approaches memory effect, cellular platforms therapies engineering These costly broad loss and both for cancer and mitigate both intracellular for modification treatment CDX immune and to need increase cancer like future applicability, target to treatment other to checkpoint of relapse. create
broad expect of Mike building Mike? this more intellectual financial now call later and detailed of continue go over more Chief our discussion a Accounting to data to a share our We turn Officer, position out to the year. property through I'll results. Jacobsen, our
